author-photo

Marco Sborgia

Sapienza University of Rome

22

Papers

842

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden.

2020 BMJ
Show All
- Source
- Cite
- Save
Citations (1)
Long-term results of all- trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

2019 Leukemia
Show All
- Source
- Cite
- Save
Citations (28)
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

2019 Haematologica
Show All
- Source
- Cite
- Save
Citations (11)
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia

2018 Leukemia
Show All
- Source
- Cite
- Save
Citations (8)
PML–RARα kinetics and impact of FLT3 –ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy

2016 Leukemia
Show All
- Source
- Cite
- Save
Citations (54)
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (124)
Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series.

2014 Blood
Show All
- Source
- Cite
- Save
Citations (12)
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

2011 Blood
Show All
- Source
- Cite
- Save
Citations (191)
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.

2011 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (21)
High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

2008 Blood
Show All
- Source
- Cite
- Save
Citations (9)